The previous earnings report from Verastem (VSTM) was filled with volatility and surprises. As I outlined in my last piece, Verastem's Earnings - Is It a Buy Now?, Verastem is a company filled with … [Read more...] about Another Quarter of Growth for Verastem…Is It Enough?
Lackluster ASCO Results for Verastem and AVEO – Part 2
As discussed in part one of this two part series, both Verastem and AVEO appear to be going to the ASCO conference this weekend with minimal updates pertaining to their pipeline. With volatility and a … [Read more...] about Lackluster ASCO Results for Verastem and AVEO – Part 2
Lackluster ASCO for Verastem and AVEO
Given Verastem's (VSTM) depressing price movement since reaching $10 in 2018 and AVEO's volatile start to 2019, neither company has brought forth any interesting data for presentation at ASCO 2019. … [Read more...] about Lackluster ASCO for Verastem and AVEO
Verastem’s Earnings: Is It a Buy Now?
Verastem (VSTM) reported earnings on May 9th after the close of the American market and proceeded to plunge 28% during Friday's trading session. What was the cause of this selloff? Here are three big … [Read more...] about Verastem’s Earnings: Is It a Buy Now?
Can Verastem Shake the DownTrend?
Last week Verastem presented additional Copiktra data at the Leerinks Health Care Conference followed by a Q&A session by analysts. The webcast can be accessed here. In this article, I discuss the … [Read more...] about Can Verastem Shake the DownTrend?
(Nasdaq: VSTM) Verastem, Better Quality of Life? A Patients Perspective
Lymphoma Patients Want and Need A Better Quality Of Life As a Lymphoma survivor, I can say unequivocally, that TO MUCH TIME is spent in the chemo wing, away from our families. Therefore, as … [Read more...] about (Nasdaq: VSTM) Verastem, Better Quality of Life? A Patients Perspective
Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
Overview Wednesday October 24th, 2018 the stock market was slashed across the board with the DOW erasing all its gains for the year and dripping red. The Nasdaq was hit with equal force. Comments from … [Read more...] about Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
VSTM Overaction to Black Box Label Creates Buying Opportunity
For months Verastem Oncology (VSTM) investors have been eagerly awaiting the FDA's decision on it's lead product Duvelisib; a PI3K-δ (delta) and PI3K-γ (gamma) inhibitor that was granted Orphan Drug … [Read more...] about VSTM Overaction to Black Box Label Creates Buying Opportunity
Market Hasn’t Grasped the Magnitude of GALT Phase1b Keytruda Combo Study
Today September 20th Galectin Therapeutics (NASDAQ: GALT) announced promising results from their phase 1b clinical trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial. … [Read more...] about Market Hasn’t Grasped the Magnitude of GALT Phase1b Keytruda Combo Study
You must be logged in to post a comment.